BeiGene Price to Free Cash Flow Ratio 2014-2024 | ONC
Historical price to free cash flow ratio values for BeiGene (ONC) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| BeiGene Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-01-03 |
180.82 |
|
0.00 |
| 2024-09-30 |
224.51 |
$-9.75 |
0.00 |
| 2024-06-30 |
142.67 |
$-12.32 |
0.00 |
| 2024-03-31 |
156.39 |
$-14.31 |
0.00 |
| 2023-12-31 |
180.36 |
$-16.47 |
0.00 |
| 2023-09-30 |
179.87 |
$-16.84 |
0.00 |
| 2023-06-30 |
178.30 |
$-21.30 |
0.00 |
| 2023-03-31 |
215.53 |
$-21.54 |
0.00 |
| 2022-12-31 |
219.94 |
$-17.67 |
0.00 |
| 2022-09-30 |
134.82 |
$-20.07 |
0.00 |
| 2022-06-30 |
161.85 |
$-19.66 |
0.00 |
| 2022-03-31 |
188.60 |
$-20.44 |
0.00 |
| 2021-12-31 |
270.93 |
$-16.83 |
0.00 |
| 2021-09-30 |
363.00 |
$-15.21 |
0.00 |
| 2021-06-30 |
343.19 |
$-12.40 |
0.00 |
| 2021-03-31 |
348.08 |
$-11.23 |
0.00 |
| 2020-12-31 |
258.39 |
$-16.78 |
0.00 |
| 2020-09-30 |
286.44 |
$-16.41 |
0.00 |
| 2020-06-30 |
188.40 |
$-18.10 |
0.00 |
| 2020-03-31 |
123.11 |
$-15.43 |
0.00 |
| 2019-12-31 |
165.76 |
$-13.99 |
0.00 |
| 2019-09-30 |
122.46 |
$-14.06 |
0.00 |
| 2019-06-30 |
123.95 |
$-11.70 |
0.00 |
| 2019-03-31 |
132.00 |
$-12.88 |
0.00 |
| 2018-12-31 |
140.26 |
$-11.84 |
0.00 |
| 2018-09-30 |
172.22 |
$-5.50 |
0.00 |
| 2018-06-30 |
153.73 |
$-2.88 |
0.00 |
| 2018-03-31 |
168.00 |
$-1.99 |
0.00 |
| 2017-12-31 |
97.72 |
$-0.80 |
0.00 |
| 2017-09-30 |
103.46 |
$-3.59 |
0.00 |
| 2017-06-30 |
45.00 |
$-4.61 |
0.00 |
| 2017-03-31 |
36.61 |
$-3.64 |
0.00 |
| 2016-12-31 |
30.36 |
$-3.64 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
